GEN Exclusives

More »

GEN Poll

More »
Feb 11, 2013

Biopharma Payment Crackdown

Manufacturers of branded and generic drugs, biologicals, devices, or medical supplies subject to reimbursement under Medicare, Medicaid, or the Children's Health Insurance Program now must report to the federal government data on their payments to physicians or teaching hospitals starting in August, under new regulations. The rules—required under section 6002 of President Obama’s Affordable Care Act (ACA)—require manufacturers to report their data on payments or “transfers of value” by March 31, 2014, and every year thereafter to the Centers for Medicare & Medicaid Services (CMS). (For more on the new regulations, click here.) What kind of an effect do you think this will have on the biopharma industry?

Will having to report data on payments to doctors have a negative effect on the biopharma industry?

Yes
 
  30.4%
No
 
  69.6%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?